Fairvalue-Calculator Fairvalue-Calculator
EN DE

Fuse Medical, Inc (FZMD) Fair Value & Analysis

Healthcare · US · Market cap $1.5M

Price$0.0200
Fair Value$0.0201
Upside+0.6%
Quality92/100
Evidence: High Range $0.0189 – $0.0213

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Fuse Medical, Inc (FZMD) currently trades at $0.0200, while our model-based Fair Value estimate is $0.0201 — implying the stock looks roughly 0.6% undervalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Fuse Medical, Inc. manufactures and distributes medical devices in the United States. The company provides orthopedic implants, including internal and external fixation products; upper and lower extremity plating and total joint reconstruction implants; soft tissue fixation and augmentation for sports medicine procedures; and full spinal implants for trauma, degenerative disc disease, and deformity indications. It also provides osteo-biologics and regenerative products, which include human allografts, tendons, substitute bone materials, and regenerative tissues. The company serves hospitals, medical facilities, and sub-distributors. Fuse Medical, Inc. is based in Farmers Branch, Texas.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Fuse Medical, Inc (FZMD) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $0.0201 versus a price of $0.0200 — about +1% (undervalued). Model-based estimate, not financial advice.
What is the fair value of FZMD?
Our 21-model fair value for Fuse Medical, Inc is $0.0201 (as of Jun 26, 2026), built from audited fundamentals. The current price is $0.0200.
What is the quality score of FZMD?
Fuse Medical, Inc has a Quality Score of 92/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.